PMID: 16626284Apr 22, 2006Paper

MOZ fusion proteins in acute myeloid leukaemia

Biochemical Society Symposium
Philip J F TrokeDavid M Heery

Abstract

MOZ (monocytic leukaemia zinc finger protein; also known as ZNF220 or MYST3) is a member of the MYST family of protein acetyltransferases. Chromosomal translocations involving the MOZ gene are associated with AML (acute myeloid leukaemia), suggesting that it has a role in haematopoiesis. Recurrent reciprocal translocations fuse the MOZ gene [or the gene encoding MORF (MOZ-related factor); also known as MYST4] to genes encoding the nuclear receptor co-activators CBP [CREB (cAMP response element-binding protein)-binding protein], p300 or the p160 protein TIF2 (transcription intermediary factor 2). The resulting fusion proteins can transform haematopoietic progenitors in vitro, and induce myeloproliferative disease in mice. Recent insights into the molecular mechanisms underlying these effects indicate that MOZ fusion proteins interfere with the activities of transcription factors such as nuclear receptors, p53 and Runx proteins. Our studies suggest that subverting the function of cellular CBP and p300 proteins may play a key role in this process. Here we review the recent progress in understanding the role of MOZ fusion proteins in the aetiology of AML.

Citations

Apr 24, 2009·Blood Cells, Molecules & Diseases·Lan WangStephen D Nimer
Jan 26, 2013·Immunology·Flor M Perez-CampoGeorges Lacaud
Mar 7, 2013·Genes, Chromosomes & Cancer·Juan Miguel MosqueraCristina R Antonescu
Jan 3, 2007·Drug Discovery Today·David M Heery, Peter M Fischer
Oct 30, 2016·American Journal of Physiology. Lung Cellular and Molecular Physiology·Isaac K Sundar, Irfan Rahman
Sep 27, 2008·Leukemia·A MuratiUNKNOWN Groupe Francophone de Cytogénétique Hématologique
Sep 7, 2007·Leukemia·S EsteyriesM-J Mozziconacci
Sep 5, 2018·The American Journal of Surgical Pathology·Pedram ArganiCristina R Antonescu
Oct 19, 2007·Expert Reviews in Molecular Medicine·Jeroen H Roelfsema, Dorien J M Peters
Sep 7, 2007·Journal of Pediatric Hematology/oncology·Mohamed AbdelhaleemSheila Weitzman
Jul 5, 2007·Endocrine Reviews·David M LonardBert W O'Malley
Mar 28, 2018·Current Oncology Reports·Marc El BeainoAnthony P Conley
Oct 22, 2009·Cancer Research·Bert W O'Malley, Rakesh Kumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.